Comprehensive Analysis of Conditional Survival in Radiation-treated Patients With Gynecologic Malignancies Using the SEER Database.

Objectives: In this study, we report conditional survival rate for gynecologic malignancies using Surveillance, Epidemiology, and End Results (SEER) database for patients who have received treatment with radiation therapy.

Methods: Utilizing the SEER 22 database and SEER*Stat 8.4.3, regional gynecologic malignancies (cervix uteri, corpus uteri, vagina, vulva) treated with external beam radiation therapy (EBRT), brachytherapy, or both, were identified between 2000 and 2020. 5-year CS was calculated annually for each type of cancer treated with different types of therapies up to 5 years post diagnosis. The timeframes for percentages of survived patients are 12 to 72, 24 to 84, 36 to 96, 48 to 108, and 60 to 120 months, which gives the percentage of patients surviving up to 5 years at 1 to 5 years from when patients received diagnosis.

Results: There were 59,441 patients who received radiation in the initial cohort. This was further subdivided into 24,073 (40%) patients who received EBRT only, 18,528 (31%) who received brachytherapy only, and 16,840 (28%) who received combined EBRT and brachytherapy. 5-year CS was calculated each year after initial diagnosis up to 5 years after. For all types of cancers that were analyzed, the 5-year CS increased as the year after diagnosis increased.

Conclusions: CS is an effective method to prognosticate patients over time. In our cohort of patients with gynecologic malignancies treated with radiation, the overall trends for 5-year CS were similar across any treatment modality. These findings may help elucidate statistics for survivorship care and may help develop evidence-based policies.